Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy
21.5.2026 14:05:00 CEST | Business Wire | Press Release
A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/
A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data.
The novel system, called CMR-CLIP, is designed to interpret cardiac MRI scans by connecting moving images of the heart with corresponding clinical radiology reports. In testing, it significantly outperformed general-purpose AI models, in some cases by more than 35%. The system also showed strong potential for improving cardiac imaging analysis, case retrieval and clinical decision support.
“This work demonstrates that domain-specific foundation models can significantly outperform general-purpose AI systems in specialized clinical applications,” said Ding Zhao, associate professor in Carnegie Mellon University’s Department of Mechanical Engineering and co-principal investigator on the study. “By designing models that reflect the structure and complexity of cardiac MRI data, rather than adapting generic image models, we can unlock new levels of performance and clinical utility.”
David Chen, Ph.D., of Cleveland Clinic, a co-principal investigator on the project, emphasized the clinical implications of the work. “Cardiac MRI interpretation is highly specialized and time intensive. Systems like CMR-CLIP have the potential to support clinicians through automated screening, and interpretation support, particularly in settings where expert readers are limited. Such reader assistant tools are critical to improving patient access to this powerful diagnostic technology.”
Cardiac MRI is widely regarded as the gold standard for evaluating heart structure, function and tissue health. A single scan can provide a comprehensive view of the heart, including pumping performance, muscle damage, blood flow and structural abnormalities. However, each study can contain hundreds to thousands of images across multiple views and time points. Even for trained specialists, interpreting a single exam can take 40 minutes or more. Because the technology is expensive and concentrated in major medical centers, there is a limited supply of experts available to meet growing clinical demand.
This combination of complexity and limited data has also made cardiac MRI one of the most challenging domains for AI. Most machine learning systems rely on large, carefully labeled datasets, but in cardiac imaging, expert annotations are scarce, time-consuming to produce and costly to scale.
To overcome this barrier, the research team leveraged a resource already embedded in routine clinical workflows: radiology reports. Every cardiac MRI exam is paired with a written summary in which clinicians document key findings in an “impression” section. Instead of relying on manual labels, the team trained CMR-CLIP to align MRI image sequences with these natural language clinical summaries, enabling the model to learn directly from how physicians describe and interpret scans in practice.
Rather than treating cardiac MRI as a collection of static images, CMR-CLIP represents each study as a video of the beating heart. The model processes multiple standard views of the heart alongside time-resolved sequences that capture motion and tissue behavior. This lets the model capture both structure and movement, much like a cardiologist does when reviewing a scan.
Trained on more than 13,000 de-identified real patient studies from Cleveland Clinic, the system learned from over a million images and hundreds of thousands of motion sequences collected over more than a decade. When tested, CMR-CLIP was able to identify cardiac conditions in a “zero-shot” setting, meaning it had never been directly trained on those specific labels, simply by matching images to descriptive prompts like “enlarged left ventricle.”
Even more striking, with just a single example of a condition, CMR-CLIP could often match the performance of other systems that required dozens of labeled cases. In more specialized diagnostic tasks, the model reached near-clinical levels of performance, including accuracy rates as high as 99% for certain heart conditions. It also demonstrated the ability to search through large databases of scans using natural language, retrieving similar cases in a way that could one day help clinicians quickly compare patients with rare or complex presentations.
A key test of whether the system was truly learning meaningful representations came when it was evaluated outside the institution where it was trained. The model still performed strongly on two entirely separate datasets (one collected in France, one in Cleveland Clinic Florida), suggesting it could generalize beyond a single hospital system.
“This work highlights a new direction for medical AI by showing how large-scale clinical data can be used to train models without requiring time-consuming manual labeling,” said Deborah Kwon, M.D., Director of Cardiac MRI at Cleveland Clinic, clinical lead and co-author of this study. “This technology has the potential to not only improve efficiency but also quality of reporting to support more consistent and clinically meaningful interpretations, as well as serve as an important teaching tool in a highly specialized and complex imaging field.”
Looking ahead, the research team plans to extend the model to additional cardiac imaging sequences, including perfusion imaging, T2-weighted imaging and parametric mapping, as well as explore applications in automated report generation and interactive clinical decision support systems in resource limited applications. This research was published in Nature Communications. The CMR-CLIP codebase is publicly available at: github.com/Makiya11/CMRCLIP.
About the College of Engineering: The College of Engineering at Carnegie Mellon University is a top-ranked engineering college that is known for our intentional focus on cross-disciplinary collaboration in research. The College is well-known for working on problems of both scientific and practical importance. Our “maker” culture is ingrained in all that we do, leading to novel approaches and transformative results. Our acclaimed faculty have a focus on innovation management and engineering to yield transformative results that will drive the intellectual and economic vitality of our community, nation, and world.
About Cleveland Clinic
Cleveland Clinic is a nonprofit multispecialty academic medical center that integrates clinical and hospital care with research and education. Founded in 1921 by four renowned physicians with a vision of providing outstanding patient care based upon the principles of cooperation, compassion and innovation, Cleveland Clinic has pioneered many medical breakthroughs, including coronary artery bypass surgery and the first face transplant in the United States. Cleveland Clinic is consistently recognized in the U.S. and throughout the world for its expertise and care. Among Cleveland Clinic’s 83,000 employees worldwide are more than 6,600 salaried physicians and researchers, and 21,900 registered nurses and advanced practice providers, representing 140 medical specialties and subspecialties. Cleveland Clinic is a 6,725-bed health system that includes a 173-acre main campus near downtown Cleveland, 23 hospitals, 300 outpatient facilities, including locations in northeast Ohio; Florida; Las Vegas, Nevada; Toronto, Canada; Abu Dhabi, UAE; and London, England. In 2025, there were 15.9 million outpatient encounters, 343,000 hospital admissions and observations, and 336,000 surgeries and procedures throughout Cleveland Clinic’s health system. Visit us at clevelandclinic.org. Follow us at x.com/CleClinicNews. News and resources are available at newsroom.clevelandclinic.org.
Editor’s Note:Cleveland Clinic News Service is available to provide broadcast-quality interviews and B-roll upon request.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260521762286/en/
Contacts
Alicia Reale, 216.408.7444, realeca@ccf.org
Kaitlyn Landram, 412.715.1511, klandram@andrew.cmu.edu
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Presents New Data on ALYFTREK ® at European Cystic Fibrosis Conference5.6.2026 18:00:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating the long-term safety and efficacy profile of the medicine. The data, presented at the European Cystic Fibrosis Conference, show children ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including those who are homozygous for the F508del mutation (F/F) and those who have F508del/minimal function mutations (F/MF)on ALYFTREK had further improvement in CFTR function from a TRIKAFTA ® baseline as measured by sweat chloride (SwCl), with 65% having achieved SwCl <30 mmol/L after treatment with ALYFTREK. Vertex also presented Phase 3 data of children ages 1 to <2 with TRIKAF
Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi5.6.2026 13:00:00 CEST | Press Release
Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605704506/en/ K Pro, Owkin's AI scientist for biology, powered by multimodal patient data for smarter biopharma decision making. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi’s immunology pipeline. This new collaboration represents the next evolution in the partnership. During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built
DFNS Rebrands as the Core Banking Platform for Digital Assets5.6.2026 12:41:00 CEST | Press Release
DFNS today announced a rebrand, marking its evolution from a wallet infrastructure to the first core banking platform for digital assets. The company is introducing a new logo, website, and market position as fintechs and institutions move their products and operations onchain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603859127/en/ Banks, fintechs, asset managers, trading firms, payment providers, market infrastructures, and clearing houses have stopped asking how to "add crypto." They're asking how to run financial products, controls, workflows, and client services on blockchain rails, with the reliability expected of core infrastructure. Some are going further still, exploring whether the blockchain can serve as the ledger itself, where an account is an onchain object rather than a row in a database. Where IBANs, virtual accounts, and blockchain wallets converge into one governed financial account. “DFNS was built
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.6.2026 12:30:00 CEST | Press Release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to seventeen newly hired non-executive employees. The equity awards were granted on June 1, 2026 and consisted of options to purchase an aggregate of 157,000 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 74,700 shares. The options have an exercise price per share equal to $14.19, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restrict
Renewable Electricity, Soft Wheat Flour From Regenerative Agriculture, Initiatives to Support Local Communities: Barilla Shares These and Other Projects in “Stories of Sustainability.”5.6.2026 10:00:00 CEST | Press Release
A slimmer Tagliatelle pack that saves 150 tons of cardboard and cuts transport-related CO₂ emissions by 20%1; ready-made sauce jars made with around 65% recycled glass; the progressive scaling of regenerative agriculture practices across Barilla’s value chain and initiatives supporting inclusion and equal opportunities across the Group’s production sites and communities. These are just some of the “sustainability” stories the Barilla Group is sharing on World Environment Day with the publication of its 2025 Sustainability Report. The report comes just after Barilla was named the world’s most reputable company in the food sector for the third year running and, for the first time, ranked among the global top 10 in the Global RepTrak 100 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603162436/en/ “The future of the planet will increasingly depend on our ability to spread culture and education,” says Paolo Barilla, Vic
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom